BioPharmSignal logoBioPharmSignal

Biotech News

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics (STIM)NeuroneticsCommercial

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting

Open original release

Related news

XAIRBeyond Air2026-06-01 12:00 EST

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

STIMNeuronetics2026-06-02 20:30 EST

Neuronetics Appoints Robert Greene as Senior Vice President Sales

STIMNeuronetics2026-06-02 12:32 EST

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

XTNTXtant Medical2026-05-06 12:00 EST

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

IARTIntegra LifeSciences2026-05-05 10:00 EST

Integra LifeSciences Announces Leadership Transition

RXSTRxSight2026-04-08 20:05 EST

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

OMOutset Medical2026-04-06 20:05 EST

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

XAIRBeyond Air2026-04-01 13:00 EST

Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

View all latest news

Neuronetics

Neuronetics is a medical device company focused on neurostimulation for depression and mental-health treatment. Its business is centered on procedure-based adoption of non-drug therapy.

Recent company news

STIMNeuronetics2026-06-02 20:30 EST

Neuronetics Appoints Robert Greene as Senior Vice President Sales

STIMNeuronetics2026-06-02 12:32 EST

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

STIMNeuronetics2026-05-14 12:32 EST

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

STIMNeuronetics2026-05-05 11:50 EST

Neuronetics Reports First Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-04-29 20:30 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.81 USD
Market cap
108.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States